HMG 150 IU

DRAGON PHARMA HMG 150 IU

Dragon Pharma HMG 150 IU represents a comprehensive fertility restoration and spermatogenesis support solution for athletes, bodybuilders, and men concerned about reproductive health in the United States. Human Menopausal Gonadotropin (HMG) is a unique therapeutic preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity derived from the urine of postmenopausal women. Each 2 mL vial contains 150 International Units (IU) of highly purified gonadotropin activity, manufactured under strict pharmaceutical standards to ensure maximum purity, biological activity, and reliability. Unlike HCG which provides only LH-like activity, HMG offers the complete hormonal profile necessary for full spermatogenesis restoration—making it the gold standard for serious fertility recovery after anabolic steroid use, during post-cycle therapy, or for addressing male factor infertility.

DRUG COMPOSITION

Each vial contains 150 International Units (IU) of Human Menopausal Gonadotropin as a lyophilized white powder. HMG is a highly purified extract from the urine of postmenopausal women, containing approximately 75 IU of follicle-stimulating hormone (FSH) activity and 75 IU of luteinizing hormone (LH) activity per 150 IU vial. The preparation contains both gonadotropin hormones in their natural ratio, providing the complete hormonal signal needed for spermatogenesis initiation and maintenance. The product may contain small amounts of human albumin as a stabilizer but contains no additional excipients or preservatives that could interfere with biological activity. The lyophilization process ensures stability and extended shelf life while maintaining the delicate tertiary structure of these glycoprotein hormones essential for receptor binding and signal transduction.

PHARMACEUTICAL FORM

Sterile lyophilized powder for injection in a 2 mL glass vial sealed with a rubber stopper and aluminum cap. The lyophilized form offers superior stability compared to liquid preparations, with extended shelf life and reduced risk of microbial contamination or hormone degradation. The powder reconstitutes quickly with bacteriostatic water or sterile saline, forming a clear to slightly opalescent solution suitable for intramuscular injection. Each vial is individually packaged with tamper-evident seals and includes batch-specific quality control documentation verifying both FSH and LH biological activity. The 2 mL volume allows for flexible reconstitution and accurate dosing based on individual therapeutic needs. Special handling instructions are included to maintain hormone integrity during reconstitution and administration.

PHARMACEUTICAL GROUP AND ATC CODE

HMG belongs to the therapeutic category of gonadotropins (ATC code: G03GA). According to the WHO Anatomical Therapeutic Chemical Classification System, it falls under gonadotropins and other ovulation stimulants. In reproductive medicine, it's classified as a menotropin containing both FSH and LH activity. For male fertility applications, it's categorized as a spermatogenesis-stimulating agent that acts directly on Sertoli and Leydig cells in the testes. Unlike recombinant FSH products that contain only FSH activity, HMG provides the natural combination of both gonadotropins necessary for complete testicular function restoration, making it particularly valuable for addressing steroid-induced infertility or hypogonadotropic hypogonadism.

PHARMACOLOGICAL PROPERTIES

HMG exerts its effects through the combined action of its two component hormones: FSH stimulates Sertoli cells in the seminiferous tubules, promoting spermatogenesis initiation and supporting developing sperm cells. LH stimulates Leydig cells to produce testosterone, which is essential for sperm maturation and provides the hormonal environment necessary for spermatogenesis. According to research published in the Journal of Clinical Endocrinology & Metabolism, the combination of FSH and LH in HMG is significantly more effective for restoring spermatogenesis than LH activity alone (as with HCG). FSH increases testicular volume, improves sperm count and morphology, while LH-derived testosterone supports libido, erectile function, and overall masculine characteristics. The natural 1:1 ratio in HMG mimics physiological conditions for optimal spermatogenic response.

THERAPEUTICAL INDICATIONS

Dragon Pharma HMG 150 IU is indicated for: restoration of spermatogenesis and fertility after anabolic steroid-induced suppression, treatment of hypogonadotropic hypogonadism (secondary hypogonadism), management of male factor infertility with low sperm counts or poor morphology, support during post-cycle therapy to accelerate testicular recovery, enhancement of testicular volume and function during bridging periods between cycles, treatment of oligospermia or azoospermia of pituitary origin, and as part of comprehensive hormonal restoration protocols for men with compromised reproductive health. It's particularly valuable for bodybuilders and athletes who have used suppressive compounds and seek to restore fertility, for men planning conception, and for those experiencing testicular atrophy from prolonged androgen use.

DOSES AND METHOD OF ADMINISTRATION

Reconstitute the 150 IU vial with 1-2 mL of bacteriostatic water, gently swirling (not shaking) to dissolve the powder. Standard dosing protocols: 75-150 IU administered intramuscularly every other day or three times per week. For fertility restoration: 150 IU every other day. For maintenance during cycles: 75 IU twice weekly. For post-cycle recovery: 150 IU every other day for 4-8 weeks. Administration should be intramuscular in gluteal, quadriceps, or deltoid muscles, rotating injection sites. Treatment duration typically ranges from 8-24 weeks depending on spermatogenic recovery goals. Blood tests for testosterone, LH, FSH, and semen analysis at 8-12 week intervals help monitor progress and adjust dosing. Always begin with lower doses to assess individual response and tolerance.

CYCLE/STACKING

HMG stacks synergistically with various compounds to optimize reproductive health outcomes. Combine with HCG 5000 IU for enhanced LH activity and testicular testosterone production during fertility protocols. Stack with Clomid for comprehensive HPTA stimulation combining direct gonadotropin support with hypothalamic-pituitary modulation. For enhanced results in severe suppression cases, add Kisspeptin 10 mg to stimulate endogenous GnRH release alongside exogenous gonadotropins. During anabolic cycles when maintaining fertility is desired, combine with Proviron which may help maintain sperm quality despite androgen use. For antioxidant support of sperm health, include NAD+ to combat oxidative stress in reproductive tissues.

POST CYCLE THERAPY

HMG serves as a cornerstone of advanced post-cycle therapy protocols focused on fertility restoration. While traditional PCT agents (SERMs, aromatase inhibitors) address hormonal axis recovery, HMG provides direct testicular stimulation necessary for spermatogenesis restoration. During PCT, administer 150 IU every other day alongside traditional agents like Clomid or Nolvadex for the first 4-8 weeks. This combination addresses both the pituitary (via SERMs) and testicular (via HMG) components of recovery. HMG is particularly valuable after cycles containing compounds that strongly suppress FSH (like Deca-Durabolin, Trenbolone, or high-dose testosterone). Continue HMG for 8-12 weeks if fertility restoration is a primary goal, with semen analysis at 12 weeks to assess recovery progress. The FSH component helps restore Sertoli cell function and sperm production more effectively than HCG alone.

SIDE EFFECTS

HMG is generally well-tolerated with appropriate dosing. Common side effects include injection site reactions (pain, redness, swelling), fluid retention, breast tenderness or enlargement (gynecomastia) due to increased estrogen conversion from stimulated testosterone production, and mood changes. Rare but serious side effects include ovarian hyperstimulation syndrome (OHSS) symptoms even in men (abdominal pain, swelling, nausea), allergic reactions to human protein components, and thrombotic events. Unlike androgenic compounds, HMG doesn't cause androgenic side effects (hair loss, acne, prostate issues) but may indirectly increase them via stimulated testosterone production. Most side effects are dose-dependent and manageable with dosage adjustments or concomitant use of aromatase inhibitors to control estrogen conversion.

CONTRAINDICATIONS

Contraindications include known hypersensitivity to HMG, human gonadotropins, or any component of the formulation. Not recommended for individuals with primary testicular failure (primary hypogonadism) as the testes cannot respond to gonadotropin stimulation. Use with caution in individuals with hormone-sensitive cancers (prostate, breast, testicular) unless under oncological supervision. Those with untreated thyroid or adrenal dysfunction should have these conditions optimized first. Not for use in women who are pregnant or could become pregnant due to potential effects on fetal development. Individuals with severe renal or hepatic impairment should consult a healthcare provider before use. Not recommended for pediatric use or individuals under 21 years of age.

OVERDOSE

Acute overdose primarily manifests as exaggerated hormonal effects: significant fluid retention, breast tenderness or enlargement, mood swings, and in extreme cases, symptoms resembling ovarian hyperstimulation syndrome (OHSS) even in men (abdominal distension, pain, nausea). In cases of significant overdose, discontinue use and monitor for thromboembolic events in susceptible individuals. Supportive care includes managing fluid balance and providing symptomatic relief. No specific antidotes exist, but symptoms typically resolve as the hormones clear from the system (approximately 24-48 hours for acute effects, longer for gynecomastia). The hormone's biological effects mean overdose consequences can persist longer than the circulating hormone levels. Always follow recommended dosing guidelines and monitor for early signs of excessive stimulation.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

Use strict aseptic technique for reconstitution and intramuscular injection to prevent infection. Rotate injection sites regularly to prevent tissue damage or abscess formation. Monitor for signs of excessive estrogen conversion (gynecomastia, fluid retention, emotional lability) and consider concomitant aromatase inhibitor use if needed. Regular blood tests to monitor testosterone, estradiol, LH, and FSH are essential during treatment. Semen analysis at 3-month intervals is recommended when used for fertility restoration. Discontinue use if severe allergic reaction occurs. Those with history of thrombosis should use with extreme caution due to increased risk with elevated estrogen. Store reconstituted solution refrigerated and use within 30 days. Avoid concurrent use with other potent gonadotropin stimulants unless under medical supervision.

INTERACTIONS WITH OTHER DRUGS

Potentiates effects of other gonadotropins and fertility medications. Aromatase inhibitors (Arimidex, Aromasin) may be needed to manage estrogen conversion from increased testosterone production. Dopamine agonists (Caber) may be required if prolactin elevation occurs. Glucocorticoids may affect gonadotropin effectiveness. Concurrent use with testosterone or other androgens may blunt spermatogenic response to HMG. Herbal supplements with estrogenic activity may exacerbate estrogen-related side effects. Always disclose all medications and supplements to healthcare providers when using HMG. Those using anticoagulants require closer monitoring due to potential effects on coagulation parameters with hormonal fluctuations.

PRESENTATION, PACKAGING

Dragon Pharma HMG 150 IU is presented in sterile 2 mL glass vials with gray rubber stoppers and green aluminum seals. Each vial contains 150 IU of lyophilized Human Menopausal Gonadotropin. Product is available in packs of 5 or 10 vials, often with bacteriostatic water included for reconstitution. Each vial is individually labeled with product name, strength (150 IU/vial), batch number, expiration date, and unique serial number for authenticity verification. Packaging includes tamper-evident features and discreet outer packaging for privacy. Instructions for proper reconstitution (gentle swirling, not shaking) and intramuscular administration are included. The green color coding distinguishes it from other Dragon Pharma hormone products for easy identification.

STORAGE

Store unopened vials at 2-8°C (36-46°F) in refrigerator. Do not freeze. Protect from light exposure. After reconstitution, store at 2-8°C (36-46°F) and use within 30 days. Do not use if solution appears cloudy, discolored, or contains particulate matter. Avoid temperature fluctuations and repeated freezing/thawing cycles. For travel, use insulated containers with cold packs. Long-term storage (over 6 months) should maintain constant refrigeration. Shelf life of unopened vials is 24 months when stored properly. Keep out of reach of children and pets. Do not use beyond expiration date printed on vial.

DELIVERY TO THE USA

All orders to the United States are shipped discreetly with guaranteed temperature-controlled delivery. We utilize specialized cold-chain shipping with temperature monitoring devices to ensure hormone integrity during transit. Most orders arrive within 7-10 business days with tracking and temperature data provided. Packaging is plain, unmarked, and includes insulated containers with cold packs for optimal temperature maintenance. We offer reshipment guarantee for orders lost in transit or compromised by temperature excursions. Express shipping options (3-5 business days) with enhanced cold-chain protection available. All packages require signature confirmation. Domestic reshipping services available for added privacy protection.

LEGAL STATUS

In the United States, HMG is available by prescription only and is classified as a prescription drug under the Food, Drug, and Cosmetic Act. It is illegal to purchase or possess without a valid prescription from a licensed healthcare provider. However, for research purposes by qualified institutions, it may be obtained through appropriate channels. This product is sold for laboratory research only. Not for human consumption, diagnosis, or treatment of any disease. Purchasers assume all responsibility for compliance with local, state, and federal laws. In sports competitions, most organizations permit therapeutic use with appropriate medical documentation. Always consult with appropriate legal counsel regarding the status in your jurisdiction.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• National Institutes of Health - HMG in Male Infertility Treatment

PROFILE

• Chemical names: Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH) - human menopausal gonadotropin
• Molecular weights: 30,000-36,000 g/mol (FSH), 28,500-29,000 g/mol (LH)
• Chemical structure: Glycoprotein hormones with alpha and beta subunits
• Percentage of anabolic activity: Indirect via testosterone stimulation (LH component)
• Percentage of androgenic activity: 0% (not androgenic)
• Active half life: 24-36 hours (intramuscular administration)
• Recommended dosage: 75-150 IU every other day
• Acne: Possible (via increased testosterone)
• Bloating (water retention): Common due to estrogen conversion
• HBR (Hepatobiliary-related): No direct hepatotoxicity
• Hepatic toxicity: None reported
• Aromatization: Does not aromatize, but increases testosterone which may
• Detection time: 3-5 days
• Anabolic/Androgenic Ratio: N/A (not anabolic steroid)
• FSH:LH ratio: Approximately 1:1 in HMG preparations
• Source: Purified from postmenopausal human urine